- Home
- RAND vs VIGL Comparison
RAND vs VIGL Comparison
Compare RAND & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- VIGL
- Stock Information
- Founded
- RAND 1969
- VIGL 2020
- Country
- RAND United States
- VIGL United States
- Employees
- RAND N/A
- VIGL N/A
- Industry
- RAND Finance: Consumer Services
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- RAND Finance
- VIGL Health Care
- Exchange
- RAND Nasdaq
- VIGL Nasdaq
- Market Cap
- RAND 80.9M
- VIGL 89.3M
- IPO Year
- RAND N/A
- VIGL 2022
- Fundamental
- Price
- RAND $18.77
- VIGL $1.78
- Analyst Decision
- RAND
- VIGL Strong Buy
- Analyst Count
- RAND 0
- VIGL 5
- Target Price
- RAND N/A
- VIGL $16.33
- AVG Volume (30 Days)
- RAND 17.9K
- VIGL 163.8K
- Earning Date
- RAND 03-10-2025
- VIGL 03-13-2025
- Dividend Yield
- RAND 27.01%
- VIGL N/A
- EPS Growth
- RAND 35.26
- VIGL N/A
- EPS
- RAND 3.42
- VIGL N/A
- Revenue
- RAND $8,559,285.00
- VIGL N/A
- Revenue This Year
- RAND N/A
- VIGL N/A
- Revenue Next Year
- RAND N/A
- VIGL N/A
- P/E Ratio
- RAND $5.60
- VIGL N/A
- Revenue Growth
- RAND 16.64
- VIGL N/A
- 52 Week Low
- RAND $13.69
- VIGL $1.49
- 52 Week High
- RAND $31.89
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- RAND 38.99
- VIGL 35.03
- Support Level
- RAND $18.62
- VIGL $1.74
- Resistance Level
- RAND $26.00
- VIGL $1.94
- Average True Range (ATR)
- RAND 1.40
- VIGL 0.16
- MACD
- RAND -0.18
- VIGL -0.02
- Stochastic Oscillator
- RAND 6.10
- VIGL 16.90
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.